Role of Ticlopidine on Adriamycin-Induced Nephropathy

References

• Vassalli P, McCluskey R T. The coagulation process and glomerular disease. Am J Med 1965; 39: 179–183
   PubMed Web of Science ®Google Scholar
• Cameron J S. Platelet in glomerular disease. Annu Rev Med 1984; 15: 175–180
   Google Scholar
• Clark W F, Naylor C D. The role of platelets in progressive glomerulosclerosis mechanisms for intraglomerular platelet activation and pathogenetic consequences. Med Hypotheses 1989; 28: 51–56
   PubMedGoogle Scholar
• Ono T, Kanatsu K, Doi T, Sekita K, Onoe C, Nagai H, Muso E, Yoshida H, Tamura T, Kawai C. Relationship of intraglomerular coagulation and platelet aggregation to glomerular sclerosis. Nephron 1991; 58: 429–436
   PubMedGoogle Scholar
• Olson J L. Role of heparin as a protective agent following reduction of renal mass. Kidney Int 1984; 25: 376–382
   PubMed Web of Science ®Google Scholar
• Pukerson M L, Joist J H, Yates J, Klahr S. Role of hypertension and coagulation in the progressive glomerulopathy of rats with subtotal renal ablation. Min Elect Metab 1987; 13: 370–376
   PubMedGoogle Scholar
• Pukerson M L, Tollefsen D M, Klahr S. N-desulfated/acetylated heparin ameliorates the progression of renal disease in rats with subtotal renal ablation. J Clin Invest 1988; 81: 69–74
   PubMedGoogle Scholar
• Zoja C, Perico N, Bergamelli A, Pasini M, Morigi M, Dadan J, Belloni A, Bertani T, Remuzzi G. Ticlopidine prevents renal disease progression in rats with reduced renal mass. Kidney Int 1990; 37: 934–942
   PubMedGoogle Scholar
• Thomson N M, Simpson I J, Peters D K. A quantitative evaluation of anticoagulants in experimental nephrotoxic nephritis. Clin Exp Immunol 1975; 19: 301–308
   PubMedGoogle Scholar
• Ogawa S, Naruse T. Effects of various antiplatelet drugs and a defibrinating agent on experimental glomerulonephritis in rats. J Lab Clin Med 1982; 99: 428–441
   PubMedGoogle Scholar
• Lianos E A, Zanglis A. GLomerular platelet-activating factors levels and origin in experimental glomerulonephritis. Kidney Int 1990; 37: 736–740
   PubMedGoogle Scholar
• Poelstra K, Hardonk M J, Koudstaal J, Bakker W W. Intraglomerular platelet aggregation and experimental glomerulonephritis. Kidney Int 1990; 37: 1500–1508
   PubMed Web of Science ®Google Scholar
• Izumino K, Asaka H I, Mizumura Y, Sasayama S. Effect of the antiplatelet agents ticlopidine and dipyridamole on experimental immune complex glomerulonephritis in rat. Nephron 1986; 43: 56–61
   PubMedGoogle Scholar
• Johnson R J, Alpers C E, Pritzl P, Schulze M, Baker P, Pruchno C, Couser W G. Platelets mediate neutrophil-dependent immune complex nephritis in the rat. J Clin Invest 1988; 82: 1225–1235
   PubMed Web of Science ®Google Scholar
• Johnson R J, Garcia R L, Pritzl P, Alpers C E. Platelets mediate glomerular cell proliferation in immune complex nephritis induced by anti mesangial cell antibodies in the ral. Am J Pathol 1990; 136: 369–374
   PubMed Web of Science ®Google Scholar
• Egido J, Robles A, Ortiz A, Ramirez F, Gonzalez E, Mampaso F, Crespo M S, Braquet P, Hernando L. Role of platelet-activating factor in adriamycin-induced nephropathy in rats. Eur J pharmac 1987; 138: 119–123
   PubMed Web of Science ®Google Scholar
• Mampaso F M, Egido J, Martinez-Monteiro J C, Bricio T, Gonzalez E, Cobo M E, Pirotzky E, Bracpet P, Hernando L. Interstitial mononuclear cell infiltrates in experimental nephrosis effect of PAF antagonist. Nephrol DiaL Transplant 1989; 4: 1037–1044
   PubMed Web of Science ®Google Scholar
• Remuzzi G, Imberti L, Rossini M, Morelli C, Carminati C, Cattaneo G M, Bertani T. Increased glomerular thromboxane synthesis as a possible cause of proteinuria in experimental nephrosis. J Clin Invest 1985; 75: 94–101
   PubMedGoogle Scholar
• Vincent J E, Zijlstra F J, Veerdonk M AM, Bonta I L. 'The effect of ticlopidine on the aggregation of rat blood Platelets and on metabolites from arachidonic acid and 8,11,14,-eicosatrienoic acid in rat platelets during aggregation, and in the rat kidney. Agents and Action 1982; 12: 377–381
   PubMedGoogle Scholar
• Henry R J. Quimica clinica: bases y principios. Proteinas. JIMS, Barcelona 1968; 205–302
   Google Scholar
• Bertani T, Rocchi G, Sacchi G, Mecca G, Remuzzi G. Adriarnycin induced glomerulosclerosis in the rat. Am J Kidney Dis 1986; VII: 12–19
   Google Scholar
• Bertani T, Poggi A, Pozzoni R, Delaini F, Sacchi G, Thoua Y, Mecca G, Remuzzi C, Donati M B. Adriamycin-induced nephrotic syndrome in rats. Lob Invest 1982; 46: 16–23
   PubMed Web of Science ®Google Scholar
• O'Donnell M P, Michels L, Kasiske B, Raji L, Kkeaine W F. Adriamycin-induced chronic proteiriuria a structural and functional study. J Lab Clin Med 1985; 106: 62–67
   PubMedGoogle Scholar
• Okuda S, Oh Y, Tsuruda H, Onoyama K, Fujimi S, Fujishima M. Adriarnycin-induced nephropathy as a model of chronic progressive glomerular disease. Kidney Int 1986; 29: 502–510
   PubMed Web of Science ®Google Scholar
• Rossmann P, Matousovic K, Bohdanecka M. Experimental adriamycin nephropathy. Fine structure, morphometry, glomerular polyanion and cell membrane antigens. J Pothol 1993; 169: 99–108
   PubMed Web of Science ®Google Scholar
• Barretti P, Viero R M, Soares V A. Effects of dietary protein, angiotensin I converting enzyme inhibition and mesangiai overload on the progression of adriamycin-induced nephropathy. Braz J Med Biol Res 1995; 28: 39–50
   PubMed Web of Science ®Google Scholar
• Weening J J, Rennke H G. Glomerular permeability and polyanion in adriamycin nephrosis in the rat. Kidney Int 1983; 24: 152–159
   PubMed Web of Science ®Google Scholar
• Poggi A, Komblihtt L, Delaini F, Colombo T, Mussoni L, Reyers I, Donati M B. Delayed hypercoagulability after a single dose of adriamycin to normal rats. 'Thromb Res 1979; 16: 639–650
   PubMedGoogle Scholar
• Maffrand J P, Defreyn G, Bernat A, Delebassee D, Tissiner A M. Reviewed pharmacology of ticlopidine. Act Méd Int-Angiologie 1983; 5(suplément n. 77)6–13
   Google Scholar
• Okasora T, Takikawa T, Utsunomiya Y, Senoh I, Hayashibara H, Shiraki K, Kasage T, Shimizu F. Suppressive effect of superoxide dismutase on adriamycin nephropathy. Nephron 1992; 60: 199–203
   PubMed Web of Science ®Google Scholar
• Tetta C, Coda R, Camusi G. Human platelet cationic proteins bind to rat glomeruli, induces loss of anionic charges and increase glomerular permeability. Agents and Actions 1985; 16: 24–26
   PubMedGoogle Scholar
• Gesualdo L, Pinzani M, Floriano J J, Hassan M O, Nagy N U, Schena F P, Emancipator S N, Abboud H E. Platelet-derived growth factor expression in mesangial proliferative glomerulonephritis. Lab lnvest 1991; 65: 160–167
   PubMedGoogle Scholar
• Border W A, Noble N A, Yamamoto T, Tomooka S, Kkagami S. Antagonists of transforming growth factor B a novel approach to treatment of glomerulonephritis and prevention of glomerulosclerosis. Kidney Int 1992; 41: 566–570
   PubMed Web of Science ®Google Scholar
• Floege J, Burns M, Alpers C E, Yoshimura A, Pritzl P, Gordon K, Seifert R A, Bowen-pope D F, Couser W G, Johnson R J. Glomerular cell proliferation and PDGF expression precede glomerulosclerosis in the remnant kidney model. Kidney Int 1992; 41: 297–309
   PubMed Web of Science ®Google Scholar